EYENOVIA, INC. Files 8-K Report

TL;DR

EYENOVIA filed an 8-K with financial statements and exhibits.

AI Summary

On May 16, 2024, EYENOVIA, INC. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating updates or disclosures related to the company's financial status. No specific material events or transactions were detailed in the provided excerpt.

Why It Matters

This filing serves as an official record of company disclosures to the SEC, providing transparency to investors regarding financial statements and exhibits.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report for financial statements and exhibits, not indicating any immediate adverse events.

Key Players & Entities

• EYENOVIA, INC. (company) — Registrant
• May 16, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-38365 (commission_file_number) — SEC File Number
• 47-1178401 (irs_number) — IRS Employer Identification No.
• 295 Madison Avenue, Suite 2400, New York, NY 10017 (address) — Principal Executive Offices
• ( 833 ) 393-6684 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.0001 — on which registered) Common stock, $0.0001 par value EYEN The Nasdaq Stock Mar

Filing Documents

• tm2414276d2_8k.htm (8-K) — 25KB
• tm2414276d2_ex5-1.htm (EX-5.1) — 7KB
• image_002.jpg (GRAPHIC) — 52KB
• 0001104659-24-062575.txt ( ) — 274KB
• eyen-20240516.xsd (EX-101.SCH) — 3KB
• eyen-20240516_lab.xml (EX-101.LAB) — 33KB
• eyen-20240516_pre.xml (EX-101.PRE) — 22KB
• tm2414276d2_8k_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. As previously announced, on April 8, 2024, Eyenovia, Inc. (the "Company") notified Leerink Partners LLC ("Leerink Partners") that it was suspending its use of and terminating the prospectus supplement (the "ATM Prospectus Supplement"), related to the potential issuance from time to time of the Company's common stock pursuant to the Sales Agreement, dated December 14, 2021, by and between the Company and Leerink Partners (the "Sales Agreement"). Other than the termination of the ATM Prospectus Supplement, the Sales Agreement remained in full force and effect. On May 16, 2024, in connection with the Company's intent to resume sales of its securities (the "ATM Shares") under the Sales Agreement, the Company will file a new prospectus supplement to its registration statement on Form S-3 (File No. 333-261638), which registration statement was previously filed with and declared effective by the Securities and Exchange Commission under the Securities Act of 1933, as amended. In connection with the resumption of sales of its securities under the Sales Agreement, the Company is filing a legal opinion of its counsel, Covington & Burling LLP, regarding the validity of the ATM Shares, which opinion is attached as Exhibit 5.1 to this Current Report on Form 8-K.

01. Financial

Item 9.01. Financial (d) Exhibits Exhibit No. Description 5.1 Opinion of Covington & Burling LLP. 23.1 Consent of Covington & Burling LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYENOVIA, INC. Date: May 16, 2024 /s/ John Gandolfo John Gandolfo Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR